Acta Scientific Pharmaceutical Sciences (ISSN: 2581-5423)

Volume 6 Issue 4 April 2022

Research Article

Overview on Lipid-based Nanoparticles: Preparations, Characterizations, and Properties

Harshil Parikh[1], Manan Patel[2,3]* and Rigved Nagarkar[2]

[1]*Teva Pharmaceutical Salt Lake City, USA*

[2]*University of the Sciences in Philadelphia, PA, USA*

[3]*Biolink Life Sciences, NC, USA*

***Corresponding Author:** Manan Patel, University of the Sciences in Philadelphia, PA, USA.

DOI: 10.31080/ASPS.2022.06.0868

Received: March 02, 2022

Published: March 30, 2022

Abstract

Lipid based nanoparticles provide the prospect of developing novel treatments owing to their unique size related characteristics. The process of integrating medicines into nanomedicines provides a novel drug discovery concept that might be used for therapeutic targeting. As a result, these nanocarriers offer tremendous potential for achieving the objective of regulated and site-specific medication, and also have captivated the interest of researchers. As a result of their pharmacological and reversible characteristics, lipid molecules can reduce undesirable consequences and toxic effects of medication methods as contrasted to polymer counterparts. The research emphasizes the significance of nanocarriers in modifying medication drug release and pharmacokinetic characteristics if administered orally.

Keywords: Oral; Delivery; Nanoparticles; Size; Controlled Release

Introduction

Nanocarrier methods are quickly emerging as a breakthrough in fields like biotechnology, genetics, and nanomaterials. Nanostructures employ a variety of preparatory processes in the creation of Nano-sized products. The goal of nanomaterials in pharmaceuticals will be to create medicines in form of particles that may be efficiently ingested, leading in a therapeutic effect with minimal adverse effects through a controlled release drug delivery mechanism [1]. SLNs were colloidal carriers composed of solid lipids having higher melting points that create a solid foundation and are coated by an aqueous surfactant. Lipid granules for medication transportation orally are well-known for their utilization of solid lipid as just a drug delivery system [2]. For the production of SLNs, lipids such as waxes, glycerides, fat, triglycerides, oil, are utilized. These benefit nanoparticles since the lipid matrix is composed of natural lipids with a minimal risk for complications and toxicity [3].

All those are sub-micron colloidal nanocarriers with diameters varied from 50-1000 nm and made of natural lipid dissolved in water or hydrophilic surfactant mixture. These have distinctive properties like tiny size, large specific surface area, increased medication loading, and phase interface, and therefore are appealing due to the ability to increase therapeutical efficacy [4]. These carriers are innovative possible colloid delivery systems as alternatives to polymer that is similar to such an oil - in - water dispersion for parenteral, except that the fluid lipids of an emulsion have now been substituted by a solid-lipid matrix. These offer many benefits, including high biocompatibility, minimal toxic effects, and lipid soluble medicines are efficiently administered by lipid nanoparticles, and also the solution being highly stable. By use of these carriers as therapeutics has a distinct benefit in which network is made of natural elements, namely excipients having generally recognized as safe (GRAS) classification for systemic

and injectable delivery, that reduces toxicity. The toxicity of these carriers could be ascribed to the nonionic additives and preservative chemicals employed in their manufacture [5]. For *in vitro* study, carriers produced at a dose of 2.5 percent lipid has no harmful effects [6]. Particularly lipid levels greater or above 10% were demonstrated to provide an 80% survival in normal granulocyte growth. In addition, at 0.5 percent levels, certain polymeric nanocarriers caused total apoptosis. Furthermore, a maximum load capability for even a wide variety of medications, particularly those with lipid soluble characteristics, can be obtained [7]. These could be made by replacing the fluid lipid in o/w nano or micro emulsions with a lipid matrix made up of solid. Generally, a solid based matrix has several benefits over a liquid-based core [8]. Emulsions and liposomes typically exhibit a loss of encapsulating medication safety and release of drugs as uncontrolled. They have the same solid lipid-based core as polymeric loaded nanoparticles. Furthermore, they are inexpensive, and ingredients and production processes, as well as the profit margins are not significantly greater than any of those developed for development of injectable mixtures. Lipid based nanocarriers have considerable potential for improving the bioavailability of a few of the least soluble medicines. The release of drug from these carriers inside the intestine is likewise relied on lipase action for lipid-based matrix breakdown inside the gastrointestinal tract. As part of an absorption, the lipase-based complex degrades dietary lipids. The *in vitro* degradation test based upon pancreatic lipase-based complex was designed to acquire valuable data about the breakdown speed of carriers as a factor of a lipid and surfactant employed [9]. Because of presence of a range of lipid assembling morphology, the morphological characteristics improves drug solubility, the formation of assembly morphologies as just a time - dependent, and chemical composition, the physicochemical parameters of lipid drug carriers are very complicated.

Benefits

- Controlled release of drug
- Medication stability is improved;
- Medication stability is improved;
- There is no toxicity of carriers.
- Organic based solvents should be avoided.
- There are no issues with huge manufacturing or sterilizing.
- Bioavailability of trapped natural compounds is elevated.
- Chemically protection of integrated labile chemicals
- These nanoparticles are easier to design as compared to polymeric based nanoparticles
- Higher stability [10].

Drawbacks associated with SLN

- Particulate formation
- Gelation tendencies that are unexpected
- Polymeric based transition dynamics that are unanticipated
- Burst release [10].

Preparation Methods

Various methods are employed for the preparation of solid lipid nanoparticles are shown in figure 1.

Figure 1: Method of Preparation.

High-pressure homogenization

These have been utilized as a dependable approach for preparing SLN. Several producers provide affordable homogenizers in a variety of sizes. Particulate in the micron range is produced in conditions of high shear stress and cavitation force. HPH creates nano-based emulsions for parenteral diet. This forces the fluid via a tiny area at increased pressures (100-2,000 bar). Such vesicles are manufactured using cold and hot homogenization methods. In each of these cases, there is a preliminary step. The lipid-based matrix

utilized throughout this method is derived from natural lipids, lowering the potential of acute and long-term cytotoxicity [11].

Hot homogenization

Temperature above the melting point of a lipid are chosen for all procedures, which may therefore be called emulsion homogenization. At about the same temperatures, a liquid surfactant is utilized to combine lipid and medication. A rapid shear blending machine is being used to create a heated pre-emulsion, culminating inside an o/w emulsion. The solution would then be cooled, which causes the production of lipid- based crystals as well as the creation of carriers. 3-5 rounds of homogenization at 500-1,500 bar was required for creation of ideal carrier [12]. The size of the particles increases as the number of repetitions or even the pressure increases. Lastly, the nano-based emulsion is cooled down to room temperature, when lipid recrystallization occurs, resulting in the production of particles [13].

Cold homogenization

The approach was designed to address the issues associated with hot homogenization, like quicker degradation owing to rising temperature, medication loss in homogenization, and unknown polymorphic changes of a lipid owing to intricacy of crystallization. First basic stage, that involves drug solubility throughout the lipid melt, is identical. The subsequent stages are changed; the drug-consisting melt is quickly chilled with solid CO_2 or liquid nitrogen to provide a homogeneous drug distribution lipid-based matrix. A ball mill can then be used to grind the solid it into fine particles. The normal size of dust obtained would be in the 50 to 100 m range. The tiny particulates are disseminated inside the cooled liquid surfactant. The mixture been exposed to HPH to begin production [11].

Ultrasonication

Sonication or high-speed stirring or were also used to create these carriers. The technique's present in each and every individual facility. The disadvantage of this method was its larger size of particles dispersion reaching into micrometer range, and is the primary source of instability. Throughout this approach, particle gain during storage and possible metallic degradation are serious issues [14].

Solvent emulsification

Diffusion process

Organic based solvents that seem to be partly water - soluble, like methyl acetate, ethyl acetate, isopropyl acetate, benzyl alcohol, and butyl lactate, are commonly seen for this technique. To begin, the organic-based solvent and water are simultaneously filled to achieve the first equilibrium state of both stages. Lipids and medicines are dispersed in a liquid solvent before being mixed in the aqueous solution with mixing to create an o/w-based emulsion. The mixture is mixed with water (vol ratios ranging from 1:5-1:10) to enable the solvents to diffuse into continuous liquid phase. These develop naturally as a result of lipid deposition, as well as the fluid is subsequently removed through lyophilization [15,16]. The approach avoids subjecting medicines to extreme temperatures and stress, including that caused by high-speed stirring or homogenization at increased pressure. Furthermore, it's also readily upgraded [17]. The method is also applicable to hydrophobic and hydrophilic medicines. Various medicines and biomolecules were encapsulated, including tretinoin, and insulin [18], cyclosporine.

Evaporation process

The evaporation technique is utilized to create nanoparticles utilizing liquid insoluble organic solvents (e.g., cyclohexane, chloroform, toluene and dichloromethane) [19,20]. To summarize, medication and lipid are mixed inside a solvent mixture, and dispersed inside an aqueous solution to produce nano-based dispersions. The major benefit of this model is that it avoids exposing medicines to extreme temp, making it suitable for enclosing extremely thermo-labile medications. The evaporation technique has drawbacks because it needs hazardous organic solvents as well as the resultant solution is diluted, necessitating additional ultra-filtration or evaporation [21].

Supercritical fluid (ScF)

That is a rather sophisticated approach for producing SLNs. It has specific thermophysical characteristics that could be carefully tuned by small changes in pressure. It is a solvent-free method of manufacturing. The volume and capacity of liquid to liquefy chemicals increase as pressure increases, but velocity stays constant. This is a material that is over its temperature and pressure. At all these temperatures, the liquid seems to have the

following properties: It has a greater mass-transfer rate due to its fluid density, viscosity like gas, and bigger diffusivities than just a conventional fluid. The medication's great absorption in $ScCO_2$ (solvent) is necessary for rapid expansion of supercritical solutions (RESS) technique to work. The liquid is rapidly expanded through a nozzle in this procedure to transform the solute as nano or micro particles. There have been 3 main variables that govern particle development, and they include a short residence period, a limited amount of time for crystal growth, and larger particle dilution. The griseofulvin was obtained by adding a co-solvent like methanol, which increases solubility of drug in $ScCO_2$ by roughly 28 times. Using a basic capillary tip, drug loaded nanoparticles with diameters ranging from 50-250 nm were created [22].

Spray drying

This is a method of converting a liquid dispersion into medication that is similar to lyophilization. As opposed to lyophilization, this is a more cost-effective technique. Because of increased temperature, shear pressures, or partial melting of a particles, there is indeed a possibility of particle collecting. It suggested recommended lipid having boiling points greater to 70°C be chosen for spray drying. The nanocarrier levels of 1% in trehalose in water or 20% trehalose in ethanol-water combinations (10/90 v/v) produced the greatest results.

Microemulsion

The formulations preparations are biphasic, with exterior and interior media. The heated microemulsion is dispersed in cold water (2°C-3°C). The dilution procedure could be modified dependent on a combination of microemulsion. There is no additional energy used in this approach to achieve the submicron size. The fundamental conditions for creation of nanomaterials are, they'll only be generated using specific solvent which quickly disperse in to aqueous solution, while more lipid soluble solvent is used to obtain larger particle size distribution. The major benefit of this approach was its weak mechanical energy input, that is adequate [23].

Coacervation method

The method relies upon the deposition of fatty acids based alkaline salts caused by acidification. The triglycerides utilized will be in the type of alkaline salts (e.g., sodium stearate) that are distributed in an aqueous phase of a polymer-based stabilizer, like HPMC or PVA [24,25]. In following phases, medications could be dispersed inside the lipid matrix or put onto controlled carriers [26]. Medications are dissolved in ethanol and dispersed with-in lipid phase to deposit them into lipid stage. If the combination is warmed above Krafft point, a transparent micellar mixture of a lipid alkaline salt forms. The mixture then titrated dropped wise with an acidifying mixture, causing the lipid to precipitation. The acquired solution is next chilled in a water bath by constant stirring at 300 rpm till 15 ºC is achieved, after which it is chilled in a water bath continuous stirring to finish the precipitate of NLC or SLN. The technique was utilized to make insulin or glargine insulin-loaded NLCs and SLNs. The coacervation technique is the simplest approach for producing NLCs and SLNs without the use of complex equipment and solvent. This can, however, also be employed on lipid which produce alkaline salt, like fatty acids, which is not appropriate for pH-sensitive medicines.

Solvent injection method

Drugs and lipids are dispersed in an aqueous-miscible solvent using this technique. Typically, the aqueous layer is made by adding an emulsifier or a buffer mixture. With the use of syringe, the organic layer is rapidly injected into to the aqueous layer while being continuously mechanically stirred [27]. Solvent diffusion leads in the production of small droplets and lipids deposition throughout this technique. Emulsifiers are crucial for the estimation of size and size ranges. At even small doses (e.g., 0.1 percent), the size distribution is significantly decreased. Generally, as the percentage of emulsifiers rises, PDI and size immediately drop, so when it crosses the threshold level (0.5-1.5 percent), PDI and size begin to increase. As a result, the emulsifier forms and stabilizes NLCs and SLNs. Particularly, organic solvent rate of diffusion into the aqueous solution is regarded among the most essential elements influencing size [28]. After injection, 2 major processes occur concurrently. Firstly, the solvent disperses out of droplet into aqueous solution, resulting in a decrease in particle size. As a result, the lipid content inside the particles rises, resulting in the development of supersaturated areas in the aqueous medium controlled by emulsifiers [29]. Secondly, the emulsifiers lower the interfacial tension here between solvent and water, resulting in the production of tiny lipid particles just at site of injection. These molecules are split into smaller particles with roughly the very same lipid contents owing to interface pulsating and turbulence throughout solvent diffusion [30].

Some recent studies of SLN preparation and characterization are listed in table 1 below.

Drug	Method of Preparation	Characterization	Inference	References
α-tocopherol acetate (ATA)	Solvent injection-ho-mogenization	Size, zeta potential, entrapment efficiency	With the no gradual release for around ten days evaluated, NPs with size, zeta, and percent EE of 175 ± 15 nm, +35 ± 2.5 mV, and 90.58 ± 1.38 percent were produced.	[31]
Temazepam	Solvent injection method	size, %EE, zeta potential, and polydispersity index (PDI)	The findings suggest that the composition might be used as a carrier system for brain-mediated medication delivery for treatment of insomnia.	[32]
siRNA	Solvent injection method	Size, %EE	The post-treatment approach is intended to help with the manufacturing of nanocarriers for useful applications as well as the creation of new LNP-loaded nanocarriers.	[33]
Enrofloxacin	Ultrasonication and hot homogenization method	Zeta potential, %EE, size, PDI	When compared to different fatty acid- prepared formulations, stearic acid loaded formulation had greater particle size, greater PDI, and larger zeta potential.	[34]
Doxorubicin	Solvent injection method	PDI, size and zeta potential	Histological studies verified the decrease in toxicity. The findings imply that VitB6 enhanced charged reversing particles might be a unique platform for effective cancer diagnosis and therapy medicines.	[35]
Simvastatin	Solvent injection technique	Size, PDI, %EE	designed to provide an optimal mixture with smallest size as well as the best feasible entrapment, capable of sustaining release profile for more than 55 hours	[36]
Piroxicam	Solvent emulsification evaporation method	Size, PDI, %EE	Piroxicam gel demonstrated more drug penetration through skin than commercial formulations, as well as the size of a formed carrier system had such a significant influence on permeability rate.	[37]

Magnesium lithospermate B	Solvent diffusion method	Size, PDI, %EE	Following PEG-SA alteration, the size of a composition ranged between 82.57 to 53.50nm, via an enhanced drug loading (approximately 16.18 percent).	[38]
[6]-Shogaol	High-pressure homogenization	Size, %EE, Zeta potential	The composition that resulted was stable, homogenous, and dispersed. It measured 73.56 ± 5.62 nm and had a voltage of -15.2 ± 1.3 mV.	[39]
Cyclosporin-A	High-pressure homogenization	DSC, size, %EE, IR, SEM	In vitro tests indicated that GMS-loaded formulation delivered the medication quicker than GPS-loaded SLNs (in 20 hours).	[40]
Glutathione	Spray congealing	FTIR, DSC, size, %EE	SLMs comprising the medication or with other combination with some other antioxidant drug was efficient in lowering intracellular oxygen species concentrations.	[41]
Clarithromycin	High-speed homogenization	Release, drug content, PDI and size	The analysis indicate that chain length of lipid was directly connected to PDI, PS, drug content, and preparation release level.	[42]
α-Bisabolol	Hot homogenization method	PXRD, FTIR, size, zeta potential	The potential result represents that -bisabolol-preparation will have a greater capacity to transport the medication to a target location.	[43]
Doxorubicin	Emulsification method	Small angle X-Ray scattering (SAXS), Small angle neutron scattering (SANS)	The findings show that if the concentration of drug is changed, the Dox does have a distinct effect on the surface morphology of carrier as well as alters the fractality throughout the vesicle's formations.	[44]

Table 1

SLN Characterization

Various approaches and tools used for SLN characterization are mentioned below.

Size

Laser diffraction (LD)

It has the advantage of having a broad range between nanoscale to low millimeter. The LD sensitivity to tiny particles was enhanced via polarization frequency divergence scattering [45].

Figure 2: Parameters for characterization of SLN.



Figure 3: Particle Size Measurement Range by Technique.

Photon correlations spectroscopy of (PCS)

It uses particle mobility to measure the changes in reflected light. It has a range of sizes of these few nm to 3 microns. This is determined by the angle of diffraction and the radius of a particle [46].

Static light scattering (SLS)

Fraunhofer diffraction is another term for it. This is a technique in which the pattern of dispersed light is gathered from a particulate mixture and incorporated in an electromagnetic formula. It is indeed a fast and precise approach.

Dynamic light scattering (DLS)

It indicates the change in the strength of reflected light during a time interval of microseconds. Light scatters due to Brownian and is measured by compiling a correlation function.

pH and electrical surface potential

Zeta potential

It describes the number of repulsive forces or affinity among particle in an SLN aqueous medium [47].

pH-sensitive probes

A probe pH is a medical instrument that measures the action of the H+ ion in aqueous fluids. It provides data upon alkalinity or acidity of a compound based on pH. The Nernst equation is used to calculate the magnitude of electrical reactions [48].

Density

The gas pycnometer is a device that uses Boyle's law and the Archimedes concept to compute the actual densities of a solid substance. Rather than a liquid, an inert gas, primarily helium, is utilized. There are several benefits, including rapid and precise findings.

Viscosity

A device named as viscometer measures the fluid viscosity. Similar instrument known as a rheometer can be used for liquids having changing operating conditions. A viscometer could only assess flow rate under a particular operating condition. Typically, either as the item moves via the liquid and the fluid remains motionless.

Molecular mass

Gel permeation chromatography allows separation based on sample size.

Hydrophobicity of the surface

Two-phase partition

The technique divides substances into two immiscible liquids, generally nonpolar and polar, based on particular solubilities. The separating pattern is characterized by the potential chemically. Polymer and salt-polymer frameworks are 2 main kinds. pH, concentration of biomolecule, concentration of polymer, and biomolecule surface characteristics are all variables that influence stage segregation. These provide delicate settings which does not harm vulnerable molecules.

Contact angle measurement

It is the angle formed by the interaction of a liquid-solid just at interface between 2 gases or fluids. Young's equation serves as the foundation. The measuring gadget is a goniometer. During a dynamic phenomenon, a spectrum of highest angle to lowest angle may be exhibited. It was critical in estimating the wet capacity of a polymeric surface of the membrane. The angle is influenced by several parameters, including particulate heterogeneity, roughness of a surface, and shape and size of a particle [49].

Morphologies and structure

- **Transmission electron microscopy (TEM):** A highly energetic electron beam is accelerated over the sample, and collisions between these target atoms may be utilized to detect characteristics like crystalline structure and structural features like grain boundaries and deformations [50].
- **Scanning electron microscopy (SEM):** It generates analyte pictures by screening the area with such a focused beam of electron. Those electrons collide with materials and generate a variety of impulses which send signals about surface features and content.
- **Atomic force microscopy:** It includes the movement of colloidal particles or resistivity around the material. The topological mapping tracks this motion among point and layer depending mostly. Through mapping the material, they are able to achieve ultra - high resolution [51].
- **Optimal microscopy:** This is also known as light microscopy, and this is a type of electron microscope that uses light waves and a series of magnification lens to examine tiny things. To produce a micrograph, these sort of microscopes uses standard, photosensitive cameras to record the picture [52].

Properties of SLN

Improved bioavailability

Various compounds could be incorporated inside the carrier's exterior layer to improve treatment efficacy for oral delivery methods. To improve oral paclitaxel administration, wheat germ agglutinin (WGA) has been layered. Paclitaxel integration it in to a WGA-loaded carrier resulted in a fold increment residence time. In one study, the author used hydroxypropyl-beta-cyclodextrin to enhance the surfaces of paclitaxel. Dextrin does have the ability to increase lipid mobility and inhibit oxidation process [53]. Docetaxel is a taxane that has been used extensively in the treatment of lung, prostate, and breast, neck malignancies. The development of oral docetaxel is hampered by its low absorption. To improve the medication's oral administration, D-alpha-tocopherol polyethylene glycol succinate-coated carrier were created. If paired with taxotere, carrier demonstrated persistent docetaxel secretion [54]. Histone deacetylase (HDAC) inhibitor is vorinostat that successfully induces cell death and growth arrest for the treatment of T-cell lymphoma. The coupling of HDAC plus a range of DNA damaging chemicals is a promising chemotherapy strategy for cancer cell killing [55]. A research looked at the bioavailability and cytotoxicity of carrier encasing tamoxifen, a medication used to treat breast cancer. The *in vitro* drug release characteristics produced an immediate initial burst accompanied by continuous release. The delivery of nanocarriers resulted in a 1.6-fold improvement in bioavailability. Oral nanocarriers are being utilized in antitubercular treatment. Antitubercular medicines incorporated in carrier, like rifampicin, pyrazinamide, and isoniazid, have been able to decrease dosage and improve patient outcomes. The emulsion solvent diffusion method is used to create antitubercular drug-entrapped nanocarriers. Those medications improved bioavailability. Paclimer has become a standardized composition designed to aid in the long-term maintenance of increasing and systematic doses of paclitaxel [56]. The formulation is made up of polilactofate polymer-entrapped with drug, which had been created by Harper in year 1999 and then evaluated for results for non-small-cell lung cancer. Expansile may be another nanoparticle composition that used treat lung cancerous cells. This medication is unique in that it responds to an extremely acidic pH prevalent surrounding cancerous cell. The nanoparticles bind to an acidic-hydrophobic surface, causing polymer particle expansion and payload discharge. SLNs have been widely employed in infection treatment, and they're used to deliver antimicrobial drugs to treat microbial, parasite, virus, and fungal illnesses. For instance, the World Health Organization has suggested the antitubercular medication isoniazid for treatment of all types of TB. A medication with such a short half-life necessitates frequent dosage, and causes damage in the liver. Isoniazid-loaded SLNs increased bioavailability and increased circulatory retention [57]. From *in vitro* drug release study, a 3-phase design was identified, consisting of a first rapid release,

accompanied by a crest, and finally subsiding. Miconazole would be a broad-spectrum fungal medication with a low solubility in water. Miconazole loading in SLNs resulted in a 2-phase release of drug with a main eruption accompanied by late release. The carrier had a higher death rate in the diffusion disk. Lopinavir, a HIV protease inhibitor, has been utilized throughout the antiretroviral therapy. Because of hepatic metabolism and P-gp efflux, carrier act as an effective lopinavir porter. The lopinavir-entrapped carrier was sustained for 4 months at 4°C due to size and drug release. Due to enhanced lymphatic distribution, the carrier provided greater oral bioavailability than the solution version of lopinavir. Compritol 888 is now used as solid-lipid in the formulation of lopinavir-entrapped carrier [58]. Primaquine can only be used to avoid relapses of a recurrent type of malaria. Higher dosages of primaquine are known to cause hematologic and GI damage. The trapping of primaquine in carrier resulted in an excellent controlled release of a medication for 72 hours [59]. Praziquantel is now used to cure the parasite illness schistosomiasis. Because praziquantel had little impact on schistosomiasis, a research introduced it to the carrier system to see whether it may increase treatment efficiency. During a thorough investigation, it has been shown that carrier was much more effective at inducing parasite death in a shorter period of time as compared to free medication [60].

Increased permeability

The recent studies indicate the potential of numerous chemicals produced from natural sources for cancer therapy. Those compounds' anticancer properties are due to their anti-inflammatory, anti-apoptotic, antioxidant, antibacterial, vasodilating and properties. An inherent role of Vitamin E tocotrienol exhibits anticancer action in breast cancer. Oral administration of gamma-tocotrienol, on the other hand, is much less efficacious (9%). These carriers are being used as a concept for gamma-tocotrienol absorption throughout the gut to enhance permeability. Nanocarriers are employed as specific medication carriers in the treatment of cancer. To treat tumours, carriers containing medicines like methotrexate and camptothecin have been utilized. Tamoxifen, an anticancer medication, has been placed in a carrier to increase permeability and retention, as well as the medication's prolonged release after IV injection for breast cancer [61].

Increased cellular absorption

Diabetes-related hyperglycaemia is now a severe medical disease that causes nervous system and cardiovascular damage. Insulin uptake is difficult via the oral administration due to stomach acidic pH, epithelium cells of digestive system, and different enzymes. Following several study trials, carriers were seen to be transporters for peptides and proteins that are recognized for their sensitive to environmental factors. Octaarginine is now a cell-permeable protein sequence that promotes the cell absorption of some medicines [62]. If compared to nonenveloped carriers, the structure demonstrated a significantly improved hypoglycaemic impact (3-fold) in animals. For situation of insulin administration orally, these carriers have been developed with Dynasan 114 as solid-lipid matrix. To ensure the strength of glibenclamide in gastrointestinal liquid, a carrier encased in polyethylene glycol (PEG) was developed. Oral carrier resulted in a fast drop in glucose concentrations that lasted for eight hours, but free glibenclamide (5 mg/kg) administered orally lowered glucose concentration following four hours but remained at very elevated amounts in diabetic animals [63].

Toxicity reduction

Nanodiamonds are diamonds that are smaller than one millimetre in size. All of those are carbon materials formed as a result of phenomena like explosions and meteoritic encounters. Because it is not harmful to lung cell, this is safe and biocompatible. This one has a wide range of applications, including cancerous cells tracking and labelling. Those nanoparticles form noncovalent and covalent interactions to diverse molecules (e.g., protein, toxins, and cancer medicines. It was possible to analyse and identify restructured carboxylate nm size diamond. In lung cells, there's no loss in viable cells or alteration throughout the protein profile, but it did induce toxicity. Within instance of cancer treatment, nano diamonds are covalently linked to PTX [64]. Throughout testing, this mixture, while administered to immunodeficiency mouse xenografts, inhibited tumour development and cell production. Metals and metal mixtures have also been utilized in medicine for centuries. The 10 most important metals with anticancer properties are antimony, arsenic, gold, bismuth, iron, vanadium, rhodium, gallium, and titanium, platinum. Metals may form bonds with a wide range of negative charges atoms due to their diverse oxidation states. For example, the transition metal group cisplatin comprises a platinum metal ion in its core. Cis-diamminedichloroplatinum (DDP, cis-platin) is also an anticancer medication that is beneficial in treating of several types of tumours, however its usage is limited mainly due to the poor cancer-specific target and severe adverse effects

[65]. Later, in a research, biodegradable epidermal growth factor receptor (EGFR)-targeted heparin DDP particles were created by attaching one chain variable segment antiEGFR antibodies to as the ligands of target for lung disease.

Improved biocompatibility

Polymer loaded micelles are massively nanoplatforms for tumour therapy, medication delivery, and tumour imaging. Super magnetic iron oxide is often utilized as just a contrast chemical to improve blood vessel visualization. For MR image and medicinal administration, a multifunctional micelle (MFM) platform is translated to code, coupled with a lung cancer-targeting polypeptide, and enveloped with superparamagnetic iron oxide and doxorubicin. When opposed to a scrambling peptide coded MFM, LCP-coded MFM demonstrated significantly improved cell targeting in H2009 cancerous cells of lungs [66]. By combining fluorescent molecular chains and folic acid to iron oxide or silica, researchers created an aqueous soluble and compatible chemotherapeutic agents' carrier. The addition of folic acid aids in focused medication administration, while the fluorescent molecule aids in visualizing the targeted. The toxicity of cell to various cell lines has accelerated necrosis and apoptosis methods, that are driven one by one by altering the cellular structure. The only constraint which prevents Ag-NP from being widely used is its lack of biocompatibility with living organisms. By coating the Ag-NP using latex from *Euphorbia nivulia* stems, a plant, the biocompatibility of silver NPs was significantly improved. The particles are toxic to adult lung cancer cell (A549) depending on the dosage [67].

Various patents on SLN loaded drug delivery are listed in table 2.

Patent Number	Approach	Year
PCT/IB2018/001073	The formulation consists of 0.01-2.00 w percent HPMC in an aqueous phase and 0.10-10% distributed SLN for internal delivery of drug compounds.	2020
PCT/IN2018/050300	The medication coated balloon comprises a balloon with only an exterior surface covered with thin layer of an anti-proliferative medication solution. The layer holds medication with 60-70 weight percent dose or with 2 excipients.	2019
PCT/IB2017/001582	The particle had a spherical form with a thickness of 15 - 100 nm, solid lipid chosen from plant-based wax and its synthesized equivalent, and TMDSC is employed as surfactant.	2019
WO/2014/191467	This consists of a glyceride or fatty acid, an amphiphilic combination, an alkaline-earth group, and a fluorescent dye.	2014
US 2016/0030305 A1	The current invention pertains to novel (food grade) nanocarriers, as well as the manufacture or use of these particles.	2016
WO 2013/105101 A8	The particles are made with one lipid chosen from category of lipids and fatty acids, one amphiphilic or hydrophilic medication, and emulsifier.	2013

Table 2

Conclusion

These carriers had also piqued the interest of many scientists due to their superior characteristics and advantages over all other conventional drug delivery systems, as well as other colloidal carriers of solid lipid nanoparticles have proven to become a major discovery in nanomaterials owing to its excellent therapeutic potential and also as a safe carrier in medicinal delivery systems. The various synthesis procedures described have benefits and drawbacks. Several considerations must be taken while determining the best approach for preparing vehicles. Solvent injection is one of the most often used and well-studied techniques since it allows you to adjust the PDI, PS, and EE parameters of items and would be used both for lipophilic and hydrophilic medicines. An easy, quick approach could be used in research laboratory to generate nanocarriers for clinical trials. The usage of solvents, which is a significant disadvantage of such a technique, could be mitigated by removing solvent procedures like spray-drying or lyophilization. In several situations, ethanol is used which may be utilized in

wound dressings. SLN has a greater efficiency and lesser toxicity in delivering peptides. These might potentially be used for non-viral gene therapy. Such carriers have several advantages, including simple integration of hydrophobic and hydrophilic medicines, sufficient physical durability, and low price and ease of production. Because of its intrinsic properties, these are capable vehicles for the development of tailored delivery methods for clinical research studies. Therefore, these promote prolonged release in addition to efficient drug delivery.

Bibliography

1. P EKAMBARAM AAHS and KP. "Solid lipid nanoparticles- A review". 2011 (2011): 80-102.

2. Naseri N., *et al*. "Solid lipid nanoparticles and nanostructured lipid carriers: Structure preparation and application". *Advanced Pharmaceutical Bulletin* 5 (2015): 305-313.

3. Mandawgade SD and Patravale VB. "Development of SLNs from natural lipids: Application to topical delivery of tretinoin". *International Journal of Pharmaceutics* 363.1-2 (2008): 132-138.

4. 2015 pratama dan marlinda. "Solid lipid nanoparticles; a review". *Angewandte Chemie International Edition* 6.11 (1967): 951-952. 4 (3): 5-48.

5. Souto EB and Müller RH. "Lipid nanoparticles: Effect on bioavailability and pharmacokinetic changes". *Handbook of Experimental Pharmacology* 197 (2010): 115-141.

6. Schubert MA and Müller-Goymann CC. "Characterisation of surface-modified solid lipid nanoparticles (SLN): Influence of lecithin and nonionic emulsifier". *European Journal of Pharmaceutics and Biopharmaceutics* 61.1-2 (2005): 77-86.

7. Müller RH., *et al*. "Cytotoxicity of magnetite-loaded polylactide, polylactide/glycolide particles and solid lipid nanoparticles". *International Journal of Pharmaceutics* 138.1 (1996): 85-94.

8. Wissing SA., *et al*. "Solid lipid nanoparticles for parenteral drug delivery". *Advanced Drug Delivery Reviews* 56.9 (2004): 1257-1272.

9. Reithmeier H., *et al*. "Development and characterization of lipid microparticles as a drug carrier for somatostatin". *International Journal of Pharmaceutics* 218.1-2 (2001): 133-143.

10. Severino P., *et al*. "Current State-of-Art and New Trends on Lipid Nanoparticles (SLN and NLC) for Oral Drug Delivery". *Journal of Drug Delivery* 2012 (2012): 1-10.

11. Mehnert W and Mader K. "Solid lipid nanoparticles Production, characterization and applications". *Neurodevelopmental Disorders* 47 (2020): 165-196.

12. Garud A., *et al*. "Solid Lipid Nanoparticles (SLN): Method, Characterization and Applications". *International Current Pharmaceutical Journal* 1.11 (2011): 384-393.

13. Bunjes H., *et al*. "Influence of emulsifiers on the crystallization of solid lipid nanoparticles". *Journal of Pharmaceutical Sciences* 92.7 (2003): 1509-1520.

14. Eldem T., *et al*. "Optimization of Spray-Dried and -Congealed Lipid Micropellets and Characterization of Their Surface Morphology by Scanning Electron Microscopy". *Pharmaceutical Research: An Official Journal of the American Association of Pharmaceutical Scientists* 8 (1991): 47-54.

15. Trotta M., *et al*. "Preparation of solid lipid nanoparticles by a solvent emulsification-diffusion technique". *International Journal of Pharmaceutics* 257.1-2 (2003): 153-160.

16. Hu FQ., *et al*. "Preparation of solid lipid nanoparticles with clobetasol propionate by a novel solvent diffusion method in aqueous system and physicochemical characterization". *International Journal of Pharmaceutics* 239.1-2 (2002): 121-128.

17. Wavers JW. "Preparation and Characterization of Solid Lipid Nanoparticles-Based Gel for Topical Delivery". *Notes Greek Text Leviticus* 2000 (2019): 314-330.

18. Battaglia L., *et al*. "Solid lipid nanoparticles formed by solvent-in-water emulsion-diffusion technique: Development and influence on insulin stability". *Journal of Microencapsulation* 24.7 (2007): 672-684.

19. Curcio CA and Johnson M. "Structure, Function, and Pathology of Bruch's Membrane". Fifth Edit. Retina Fifth Edition. Elsevier Inc 1 (2012): 465-481.

20. Pooja D., *et al*. "Characterization, biorecognitive activity and stability of WGA grafted lipid nanostructures for the controlled delivery of Rifampicin". *Chemistry and Physics of Lipids* 193 (2015): 11-17.

21. Cortesi R., *et al*. "Production of lipospheres as carriers for bioactive compounds". *Biomaterials* 23.11 (2002): 2283-2294.

22. Garcês A., *et al*. "Formulations based on solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for cutaneous use: A review". *European Journal of Pharmaceutical Sciences* 112 (2018): 159-167.

23. He H., *et al*. "VB12-coated Gel-Core-SLN containing insulin: Another way to improve oral absorption". *International Journal of Pharmaceutics* 493.1-2 (2015): 451-459.

24. Lin C., *et al*. "Pulmonary delivery of triptolide-loaded liposomes decorated with anti-carbonic anhydrase IX antibody for lung cancer therapy". *Scientific Report* 7.1 (2017): 1-12.

25. Chirio D., *et al*. "Positive-charged solid lipid nanoparticles as paclitaxel drug delivery system in glioblastoma treatment". *European Journal of Pharmaceutics and Biopharmaceutics* 88.3 (2014): 746-758.

26. Clemente N., *et al*. "Solid lipid nanoparticles carrying temozolomide for melanoma treatment. Preliminary in vitro and in vivo studies". *International Journal of Molecular Sciences* 19.2 (2018).

27. Das S and Chaudhury A. "Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery". *AAPS PharmSciTech* 12.1 (2011): 62-76.

28. Wang T., *et al*. "Solvent injection-lyophilization of tert-butyl alcohol/water cosolvent systems for the preparation of drug-loaded solid lipid nanoparticles". *Colloids Surfaces B Biointerfaces* 79.1 (2010): 254-261.

29. Schubert MA and Müller-Goymann CC. "Solvent injection as a new approach for manufacturing lipid nanoparticles - Evaluation of the method and process parameters". *European Journal of Pharmaceutics and Biopharmaceutics* 55.1 (2003): 125-131.

30. Duong VA., *et al*. "Preparation of Ondansetron Hydrochloride-Loaded Nanostructured Lipid Carriers Using Solvent Injection Method for Enhancement of Pharmacokinetic Properties". *Pharmaceutical Research* 36.10 (2019).

31. Nasiri F., *et al*. "Preparation, optimization, and in-vitro characterization of α-tocopherol-loaded solid lipid nanoparticles (SLNs)". *Drug Development and Industrial Pharmacy* 46.1 (2020): 159-171.

32. Eleraky NE., *et al*. "Nanostructured lipid carriers to mediate brain delivery of Temazepam: Design and in vivo study". *Pharmaceutics* 12.5 (2020).

33. Kimura N., *et al*. "Development of a Microfluidic-Based Post-Treatment Process for Size-Controlled Lipid Nanoparticles and Application to siRNA Delivery". *ACS Applied Materials and Interfaces* 12.30 (2020): 34011-34020.

34. Xie S., *et al*. "Preparation, characterization and pharmacokinetics of enrofloxacin-loaded solid lipid nanoparticles: Influences of fatty acids". *Colloids Surfaces B Biointerfaces* 83.2 (2011): 382-387.

35. Sharma S., *et al*. "Vitamin B6 Tethered Endosomal pH Responsive Lipid Nanoparticles for Triggered Intracellular Release of Doxorubicin". *ACS Applied Materials and Interfaces* 8.44 (2014): 30407-30421.

36. Shah M and Pathak K. "Development and statistical optimization of solid lipid nanoparticles of simvastatin by using 23 full-factorial design". *AAPS PharmSciTech* 11.2 (2010): 489-496.

37. Mohammadi-Samani S., *et al*. "Piroxicam loaded solid lipid nanoparticles for topical delivery: Preparation, characterization and in vitro permeation assessment". *Journal of Drug Delivery Science and Technology* 47 (2018): 427-433.

38. Kang X., *et al*. "Magnesium lithospermate B loaded PEGylated solid lipid nanoparticles for improved oral bioavailability". *Colloids Surfaces B Biointerfaces* 161 (20018): 597-605.

39. Wang Q., *et al*. "Enhanced oral bioavailability and anti-gout activity of 6]-shogaol-loaded solid lipid nanoparticles". *International Journal of Pharmaceutics* 550.1-2 (2018): 24-34.

40. Sawant K., *et al*. "Cyclosporine A Loaded Solid Lipid Nanoparticles: Optimization of Formulation, Process Variable and Characterization". *Current Drug Delivery* 5.1 (2008): 64-69.

41. Trapani A., *et al*. "Glutathione-loaded solid lipid nanoparticles based on Gelucire® 50/30: Spectroscopic characterization and interactions with fish cells. *Journal of Drug Delivery Science and Technology* 47 (2018): 359-366.

42. Öztürk AA., *et al*. "Influence of glyceryl behenate, tripalmitin and stearic acid on the properties of clarithromycin incorporated solid lipid nanoparticles (SLNs): Formulation, characterization, antibacterial activity and cytotoxicity". *Journal of Drug Delivery Science and Technology* 54 (2019): 101240.

43. Sathya S., *et al*. "α-Bisabolol loaded solid lipid nanoparticles attenuates Aβ aggregation and protects Neuro-2a cells from Aβ induced neurotoxicity". *Journal of Molecular Liquids* 264 (2018): 431-441.

44. Yokaichiya F., *et al*. "Effects of doxorubicin on the structural and morphological characterization of solid lipid nanoparticles (SLN) using small angle neutron scattering (SANS) and small angle X-ray scattering (SAXS)". *Physica B: Condensed Matter* 551 (2018): 191-196.

45. Osborne DW., *et al*. "Determination of Particle Size and Microstructure in Topical Pharmaceuticals". in The Role of Microstructure in Topical Drug Product Development, N. Langley, B. Michniak-Kohn, and D.W. Osborne, Editors. 2019, Springer International Publishing: Cham (2019): 89-106.

46. Montasser I., *et al*. "Solid lipid nanoparticle-based calixn] arenes and calix-resorcinarenes as building blocks: Synthesis, formulation and characterization". *International Journal of Molecular Sciences* 14.11 (2013): 21899-21942.

47. Mishra DK., *et al*. "Engineering solid lipid nanoparticles for improved drug delivery: Promises and challenges of translational research". *Drug Delivery and Translational Research* 2.4 (2012): 238-253.

48. Plajnšek KT., *et al*. "A novel fluorescent probe for more effective monitoring of nanosized drug delivery systems within the cells". *International Journal of Pharmaceutics* 416.1 (2011): 384-393.

49. Tang K., *et al*. "Measurement for contact angle of iron ore particles and water". *ISIJ International* 58.3 (2018): 379-400.

50. Jores K., *et al*. "Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy". *Journal of Control Release* 95.2 (2004): 217-227.

51. Carrillo C., *et al*. "DNA delivery via cationic solid lipid nanoparticles (SLNs)". *European Journal of Pharmaceutical Sciences* 49.2 (2013): 157-165.

52. Sharifi M., *et al*. "Plasmonic gold nanoparticles: Optical manipulation, imaging, drug delivery and therapy". *Journal of Control Release* 311-312 (2019): 170-189.

53. Zafar N., *et al*. "Cyclodextrin containing biodegradable particles: From preparation to drug delivery applications". *International Journal of Pharmaceutics* 461.1-2 (2014): 351-366.

54. Cho HJ., *et al*. "Surface-modified solid lipid nanoparticles for oral delivery of docetaxel: Enhanced intestinal absorption and lymphatic uptake". *International Journal of Nanomedicine* 9.1 (2014): 495-504.

55. Ozaki KI., *et al*. "Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs". *Cancer Science* 99.2 (2008): 376-384.

56. Jain S., *et al*. "Polyelectrolyte stabilized multilayered liposomes for oral delivery of paclitaxel". *Biomaterials* 33.28 (2012): 6758-6768.

57. Aljaeid BM and Hosny KM. "Miconazole-loaded solid lipid nanoparticles: Formulation and evaluation of a novel formula with high bioavailability and antifungal activity". *International Journal of Nanomedicine* 11 (2016): 441-447.

58. Negi JS., *et al*. "Development of solid lipid nanoparticles (SLNs) of lopinavir using hot self nano-emulsification (SNE) technique". *European Journal of Pharmaceutical Sciences* 48.1-2 (2013): 231-239.

59. Baird JK. "Primaquine toxicity forestalls effective therapeutic management of the endemic malarias. Int *Journal of Parasitology* 42.12 (2012): 1049-1054.

60. Souza ALR De., *et al*. "In vitro evaluation of permeation, toxicity and effect of praziquantel-loaded solid lipid nanoparticles against Schistosoma mansoni as a strategy to improve efficacy of the schistosomiasis treatment". *International Journal of Pharmaceutics* 463.1 (2014): 31-37.

61. Sowmya K., *et al*. "Overview of Modern and Traditional Techniques of Permeation Enhancement for Topical Drug Deliver". *Acta Scientific Pharmaceutical Sciences* 6.1 (2022): 44-54.

62. Golan M., *et al*. "Conjugates of HA2 with octaarginine-grafted HPMA copolymer offer effective siRNA delivery and gene silencing in cancer cells". *European Journal of Pharmaceutics and Biopharmaceutics* 109 (2016): 103-112.

63. Gonçalves LMD., *et al*. "Development of solid lipid nanoparticles as carriers for improving oral bioavailability of glibenclamide". *European Journal of Pharmaceutics and Biopharmaceutics* 102.16 (2016): 41-50.

64. Llu KK., *et al*. "Covalent linkage of nanodiamond-paclitaxel for drug delivery and cancer therapy". *Nanotechnology* 21.31 (2010).

65. Peng XH., *et al*. "Targeted delivery of cisplatin to lung cancer using ScFvEGFR-heparin- cisplatin nanoparticles". *ACS Nano* 5.1 (2011): 9480-9493.

66. Guthi JS., *et al*. "MRI-visible micellar nanomedicine for targeted delivery to cancer cell". *Molecular BioSystems* 7.1 (2010): 32-40.

67. Valodkar M., *et al*. "In vitro toxicity study of plant latex capped silver nanoparticles in human lung carcinoma cells". *Materials Science and Engineering: C* 31.8 (2011): 1723-1728.